Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.52 |
| ▸ | NPY1R | P25929 | 8/20 | 0.52 |
| ▸ | NPY2R | P49146 | 6/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028934 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30028687 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30029283 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL29476450 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30787063 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30787051 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL29476470 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30029319 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30029277 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL29476500 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | NPY4R 7/4885NPY1R 18/4885NPY2R 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.